This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro and Sabrina Tavernise. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp
The Race for a Vaccine
Scientists are racing to make a vaccine for the coronavirus, collaborating across borders in what is usually a secretive and competitive field. But their cooperation has been complicated by national leaders trying to buy first claim on any breakthrough. Today, we explore how the fight to own a future coronavirus vaccine is revealing the boundaries of international solidarity.
Guest: Katrin Bennhold, Berlin bureau chief for The New York Times, spoke with Lidia Oostvogels, who researches infectious diseases with the German biotech company CureVac. For more information on today’s episode, visit nytimes.com/thedaily.
Background reading:
- The United States says it will share any vaccine breakthroughs with the world. So why did President Trump reportedly try to purchase a German biotech company that is trying to develop a shot for the coronavirus?
- The latest updates from top U.S. government scientists project that the coronavirus could kill 100,000 to 240,000 Americans — even with strict social distancing.
Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify.